Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows.

Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $ ...

The Novo Nordisk Foundation is funding the creation ... kidney disease, type 1 diabetes and several forms of cancer.” The investment comes after a report prepared for the European Federation ...

Ltd. have launched a new collaboration titled “Partnership Project for the Transition into the Fourth Decade of Thammasat ...

Novo Nordisk didn't announce a launch date or give any details about volumes. The company's Ozempic was approved to treat diabetes in China in 2021. Sales of the drug in the greater China region more ...